# Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 6.4 | nc | (nc-nc) |  | Male | 7 | 4.1 | 169.5 | (67.9-349.2) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 7 | 2.9 | 239.9 | (96.1-494.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 21 | 25.2 | 83.2 | (51.5-127.2) |  | Female | 5 | 3.0 | 164.7 | (53.1-384.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 7.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 6.4 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 24 | 22.6 | 106.4 | (68.1-158.3) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 2.5 | 198.3 | (63.9-462.8) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 5 | 4.2 | 119.8 | (38.6-279.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 9 | 5.6 | 159.6 | (72.8-303.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 12.0 | 49.9 | (18.2-108.7) |  | Male | 67 | 86.2 | 77.7 | (60.2-98.7) |
| Female | 3 | 11.5 | nc | (nc-nc) |  | Female | 73 | 81.9 | 89.2 | (69.9-112.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

61

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 13.6 | 110.0 | (61.5-181.4) |  | Male | 10 | 8.6 | 116.3 | (55.7-214.0) |
| Female | 8 | 5.3 | 151.6 | (65.3-298.7) |  | Female | 10 | 7.1 | 141.6 | (67.8-260.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 3 | 7.7 | nc | (nc-nc) |
| Female | 42 | 59.8 | 70.3 | (50.7-95.0) |  | Female | 12 | 7.4 | 162.4 | (83.8-283.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.4 | 94.2 | (34.4-205.1) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 14.5 | 96.7 | (52.8-162.2) |  |  |  |  |  |  |
| Female | 11 | 15.2 | 72.5 | (36.1-129.7) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 3.5 | 199.8 | (80.1-411.7) |  | Male | 5 | 4.9 | 102.0 | (32.9-238.0) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 5.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 38 | 43.1 | 88.1 | (62.3-120.9) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 7.5 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 8 | 4.7 | 171.5 | (73.9-338.0) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 5 | 4.1 | 121.1 | (39.0-282.6) |  | Female | 6 | 10.0 | 60.1 | (22.0-130.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 14 | 13.7 | 102.0 | (55.7-171.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 24.2 | 136.4 | (93.9-191.6) |  | Male | 165 | 175.1 | 94.2 | (80.4-109.8) |
| Female | 41 | 27.8 | 147.7 | (105.9-200.3) |  | Female | 181 | 197.1 | 91.8 | (78.9-106.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

62

# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 10 | 6.6 | 151.4 | (72.5-278.4) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 4 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 23 | 23.5 | 97.7 | (61.9-146.6) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 28 | 22.2 | 126.2 | (83.8-182.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

63

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 13.0 | 123.4 | (70.5-200.3) |  | Male | 4 | 8.7 | nc | (nc-nc) |
| Female | 7 | 4.0 | 174.7 | (70.0-359.9) |  | Female | 6 | 6.6 | 90.9 | (33.2-197.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 2.7 | 223.7 | (81.7-486.8) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 11 | 7.8 | 140.8 | (70.2-251.9) |
| Female | 53 | 54.1 | 98.0 | (73.4-128.2) |  | Female | 6 | 6.2 | 97.3 | (35.5-211.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 6.8 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 15.0 | 60.0 | (27.4-113.9) |  |  |  |  |  |  |
| Female | 15 | 12.7 | 118.4 | (66.2-195.3) |  | Female | 2 | 4.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 7 | 4.8 | 146.5 | (58.7-301.9) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 4.2 | 120.4 | (38.8-280.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 23 | 42.9 | 53.6 | (34.0-80.4) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 7.8 | 127.7 | (61.2-235.0) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 3 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.5 | nc | (nc-nc) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 16 | 10.8 | 147.6 | (84.3-239.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 11 | 12.2 | 90.3 | (45.0-161.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 21 | 22.9 | 91.6 | (56.7-140.1) |  | Male | 140 | 175.3 | 79.9 | (67.2-94.2) |
| Female | 25 | 21.1 | 118.5 | (76.7-175.0) |  | Female | 181 | 170.8 | 105.9 | (91.1-122.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

64

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 14.4 | 104.5 | (58.4-172.3) |  | Male | 21 | 8.0 | 261.2 | (161.6-399.2) |
| Female | 10 | 4.7 | 211.4 | (101.2-388.8) |  | Female | 14 | 5.0 | 281.6 | (153.8-472.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 8 | 7.2 | 111.2 | (47.9-219.1) |
| Female | 43 | 42.4 | 101.5 | (73.5-136.8) |  | Female | 7 | 6.0 | 117.6 | (47.1-242.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 5.4 | 128.5 | (51.5-264.8) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 13.8 | 115.6 | (66.0-187.8) |  |  |  |  |  |  |
| Female | 14 | 12.6 | 110.9 | (60.6-186.0) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 7 | 4.8 | 145.2 | (58.2-299.2) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 6 | 4.8 | 125.0 | (45.7-272.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 44 | 39.3 | 111.8 | (81.3-150.1) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.6 | 91.1 | (33.3-198.3) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 5.1 | 178.0 | (81.2-337.9) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 2 | 5.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 11 | 9.9 | 111.4 | (55.5-199.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 25.1 | 87.6 | (54.9-132.6) |  | Male | 183 | 165.2 | 110.8 | (95.3-128.1) |
| Female | 24 | 24.7 | 97.3 | (62.3-144.8) |  | Female | 169 | 151.4 | 111.6 | (95.4-129.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

65

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 51 | 39.6 | 128.7 | (95.8-169.2) |  | Male | 20 | 25.4 | 78.6 | (48.0-121.4) |
| Female | 16 | 15.3 | 104.7 | (59.8-170.0) |  | Female | 20 | 20.4 | 98.2 | (59.9-151.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 7.6 | 144.8 | (72.2-259.1) |  | Male | 8 | 8.2 | 97.8 | (42.1-192.7) |
| Female | 8 | 6.5 | 123.8 | (53.3-244.0) |  | Female | 11 | 7.0 | 157.8 | (78.6-282.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 27 | 22.6 | 119.2 | (78.6-173.5) |
| Female | 177 | 170.6 | 103.8 | (89.0-120.2) |  | Female | 16 | 21.2 | 75.5 | (43.1-122.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 19.0 | 110.5 | (68.4-169.0) |
| Female | 6 | 5.4 | 110.3 | (40.3-240.2) |  | Female | 8 | 8.9 | 89.5 | (38.5-176.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 40 | 43.1 | 92.7 | (66.2-126.3) |  |  |  |  |  |  |
| Female | 44 | 43.9 | 100.2 | (72.8-134.6) |  | Female | 22 | 14.5 | 151.6 | (95.0-229.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 10.2 | 58.7 | (21.4-127.7) |  | Male | 18 | 14.2 | 126.8 | (75.1-200.4) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 18 | 15.5 | 116.5 | (69.0-184.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 126 | 122.8 | 102.6 | (85.5-122.2) |
| Female | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 19 | 22.2 | 85.6 | (51.5-133.8) |  | Male | 4 | 9.6 | nc | (nc-nc) |
| Female | 12 | 13.5 | 88.8 | (45.8-155.1) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 6.0 | nc | (nc-nc) |  | Male | 5 | 5.1 | 98.5 | (31.8-229.9) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 15.9 | 106.6 | (62.1-170.7) |  | Male | 13 | 10.1 | 128.9 | (68.6-220.4) |
| Female | 25 | 11.9 | 210.0 | (135.9-310.1) |  | Female | 29 | 29.6 | 97.8 | (65.5-140.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 14.0 | 57.2 | (24.6-112.8) |  |  |  |  |  |  |
| Female | 2 | 5.0 | nc | (nc-nc) |  | Female | 50 | 38.0 | 131.4 | (97.6-173.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 64 | 71.0 | 90.1 | (69.4-115.0) |  | Male | 513 | 512.2 | 100.2 | (91.7-109.2) |
| Female | 79 | 82.4 | 95.9 | (75.9-119.5) |  | Female | 613 | 567.8 | 108.0 | (99.6-116.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

66

# Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 22.1 | 63.2 | (34.5-106.1) |  | Male | 8 | 16.4 | 48.9 | (21.1-96.4) |
| Female | 10 | 8.5 | 117.0 | (56.0-215.2) |  | Female | 10 | 14.4 | 69.5 | (33.3-127.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.2 | 112.2 | (45.0-231.2) |  | Male | 5 | 4.9 | 102.4 | (33.0-238.9) |
| Female | 6 | 4.9 | 122.6 | (44.8-266.8) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 13 | 14.9 | 87.2 | (46.4-149.1) |
| Female | 96 | 104.1 | 92.2 | (74.7-112.6) |  | Female | 16 | 12.9 | 124.0 | (70.8-201.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 12.4 | 56.5 | (22.6-116.4) |
| Female | 7 | 4.5 | 155.5 | (62.3-320.4) |  | Female | 8 | 5.4 | 147.0 | (63.3-289.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 27.1 | 118.0 | (80.7-166.6) |  |  |  |  |  |  |
| Female | 17 | 26.5 | 64.2 | (37.4-102.8) |  | Female | 5 | 9.0 | 55.6 | (17.9-129.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.0 | 83.5 | (26.9-195.0) |  | Male | 9 | 8.3 | 108.6 | (49.6-206.2) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 15 | 8.8 | 169.6 | (94.9-279.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 51 | 72.2 | 70.6 | (52.6-92.8) |
| Female | 1 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 14.8 | 40.6 | (14.8-88.3) |  | Male | 12 | 5.7 | 209.4 | (108.1-365.8) |
| Female | 11 | 8.1 | 135.5 | (67.5-242.4) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 4 | 6.9 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 11.1 | 108.3 | (55.9-189.2) |  | Male | 7 | 8.5 | 82.4 | (33.0-169.7) |
| Female | 11 | 8.3 | 132.5 | (66.1-237.1) |  | Female | 41 | 25.6 | 160.3 | (115.0-217.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 8.4 | 166.1 | (90.7-278.7) |  |  |  |  |  |  |
| Female | 9 | 2.9 | 315.0 | (143.7-598.0) |  | Female | 15 | 22.2 | 67.5 | (37.8-111.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 53 | 39.0 | 135.8 | (101.7-177.7) |  | Male | 299 | 318.7 | 93.8 | (83.5-105.1) |
| Female | 64 | 44.1 | 145.1 | (111.7-185.3) |  | Female | 381 | 351.3 | 108.5 | (97.8-119.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

67

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 4.7 | 127.6 | (46.6-277.7) |  | Male | 5 | 2.8 | 176.8 | (57.0-412.7) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 14 | 17.1 | 81.8 | (44.7-137.2) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 4.8 | 165.6 | (71.3-326.2) |  |  |  |  |  |  |
| Female | 2 | 4.3 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 17 | 15.5 | 109.6 | (63.8-175.5) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 7 | 4.0 | 174.8 | (70.0-360.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 8.4 | 166.8 | (91.1-280.0) |  | Male | 64 | 59.5 | 107.5 | (82.8-137.3) |
| Female | 3 | 8.3 | nc | (nc-nc) |  | Female | 42 | 56.9 | 73.8 | (53.1-99.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

68

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 1.6 | 317.3 | (102.3-740.5) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 5.1 | 118.6 | (43.3-258.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 23 | 19.1 | 120.5 | (76.4-180.8) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 12 | 18.5 | 64.8 | (33.4-113.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

69

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 5.8 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 5.2 | 95.7 | (30.8-223.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 2 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 17 | 19.1 | 89.1 | (51.9-142.7) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 10 | 18.1 | 55.3 | (26.5-101.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

70

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 63 | 64.5 | 97.7 | (75.1-125.0) |  | Male | 25 | 40.1 | 62.3 | (40.3-91.9) |
| Female | 16 | 23.6 | 67.8 | (38.7-110.1) |  | Female | 20 | 31.2 | 64.1 | (39.1-99.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 12.1 | 90.9 | (45.3-162.7) |  | Male | 12 | 12.9 | 92.9 | (48.0-162.3) |
| Female | 12 | 9.9 | 121.3 | (62.6-211.9) |  | Female | 8 | 10.6 | 75.6 | (32.6-149.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 30 | 35.9 | 83.6 | (56.4-119.3) |
| Female | 253 | 248.9 | 101.7 | (89.5-115.0) |  | Female | 36 | 32.4 | 111.1 | (77.8-153.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 33 | 29.1 | 113.3 | (78.0-159.2) |
| Female | 11 | 8.0 | 137.1 | (68.4-245.4) |  | Female | 24 | 13.4 | 178.5 | (114.4-265.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 97 | 67.7 | 143.3 | (116.2-174.8) |  |  |  |  |  |  |
| Female | 62 | 67.7 | 91.6 | (70.2-117.4) |  | Female | 30 | 21.7 | 138.5 | (93.4-197.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 16.2 | 98.6 | (56.3-160.1) |  | Male | 21 | 22.6 | 92.7 | (57.4-141.7) |
| Female | 7 | 4.6 | 152.1 | (60.9-313.4) |  | Female | 26 | 23.9 | 108.8 | (71.0-159.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 4.7 | 127.9 | (46.7-278.4) |  | Male | 115 | 194.7 | 59.1 | (48.8-70.9) |
| Female | 1 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 44 | 34.4 | 128.0 | (93.0-171.9) |  | Male | 9 | 15.3 | 58.7 | (26.8-111.4) |
| Female | 27 | 20.2 | 133.7 | (88.1-194.6) |  | Female | 9 | 9.2 | 97.9 | (44.7-185.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 12 | 9.4 | 127.6 | (65.9-222.9) |  | Male | 10 | 8.3 | 120.0 | (57.4-220.7) |
| Female | 0 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 25.8 | 77.6 | (47.4-119.8) |  | Male | 11 | 15.3 | 71.9 | (35.8-128.6) |
| Female | 12 | 18.7 | 64.3 | (33.2-112.4) |  | Female | 32 | 44.5 | 71.9 | (49.1-101.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 21.7 | 46.2 | (22.1-84.9) |  |  |  |  |  |  |
| Female | 7 | 7.6 | 92.5 | (37.1-190.6) |  | Female | 51 | 55.6 | 91.7 | (68.3-120.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 139 | 114.1 | 121.9 | (102.4-143.9) |  | Male | 740 | 813.5 | 91.0 | (84.5-97.8) |
| Female | 130 | 123.9 | 105.0 | (87.7-124.6) |  | Female | 846 | 852.3 | 99.3 | (92.7-106.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

71

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 2 | 6.0 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 19 | 16.3 | 116.7 | (70.2-182.2) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 8 | 19.3 | 41.4 | (17.8-81.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

72

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 5 | 8.2 | 61.3 | (19.7-143.0) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 8 | 7.7 | 104.0 | (44.8-205.0) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 4.8 | 103.4 | (33.3-241.3) |  | Male | 30 | 32.7 | 91.8 | (61.9-131.0) |
| Female | 5 | 4.1 | 122.1 | (39.3-284.9) |  | Female | 25 | 27.5 | 90.8 | (58.8-134.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

73

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 13.4 | 194.1 | (126.7-284.4) |  | Male | 6 | 8.9 | 67.7 | (24.7-147.5) |
| Female | 5 | 5.1 | 97.2 | (31.3-226.8) |  | Female | 12 | 7.4 | 161.2 | (83.2-281.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 6 | 8.0 | 75.3 | (27.5-163.8) |
| Female | 51 | 59.0 | 86.4 | (64.4-113.7) |  | Female | 8 | 7.4 | 108.5 | (46.7-213.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 6.9 | 73.0 | (23.5-170.2) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 14.9 | 113.9 | (66.3-182.4) |  |  |  |  |  |  |
| Female | 14 | 15.5 | 90.4 | (49.4-151.7) |  | Female | 5 | 5.1 | 98.0 | (31.6-228.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.6 | 138.6 | (44.7-323.5) |  | Male | 3 | 4.9 | nc | (nc-nc) |
| Female | 4 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 56 | 45.2 | 123.8 | (93.5-160.8) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 8.0 | 87.2 | (34.9-179.6) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 5 | 4.6 | 108.6 | (35.0-253.5) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 5.6 | 159.7 | (72.9-303.2) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 6 | 4.3 | 139.8 | (51.1-304.4) |  | Female | 11 | 11.4 | 96.7 | (48.2-173.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 4.9 | 164.3 | (70.7-323.7) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 13 | 13.2 | 98.3 | (52.3-168.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 24.2 | 115.9 | (77.0-167.5) |  | Male | 199 | 181.2 | 109.8 | (95.1-126.2) |
| Female | 37 | 26.5 | 139.9 | (98.5-192.8) |  | Female | 205 | 197.2 | 104.0 | (90.2-119.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

74

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 9.4 | 85.2 | (36.7-167.9) |  | Male | 5 | 6.1 | 82.3 | (26.5-192.1) |
| Female | 6 | 3.4 | 175.8 | (64.2-382.6) |  | Female | 15 | 4.4 | 339.0 | (189.6-559.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.4 | 111.6 | (40.8-243.0) |
| Female | 41 | 37.0 | 110.9 | (79.6-150.4) |  | Female | 3 | 4.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.6 | 108.4 | (34.9-253.0) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 10.0 | 119.9 | (61.9-209.4) |  |  |  |  |  |  |
| Female | 6 | 9.7 | 61.8 | (22.6-134.5) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 31 | 30.0 | 103.3 | (70.2-146.6) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.3 | 94.0 | (30.3-219.3) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.8 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 5 | 2.7 | 185.5 | (59.8-432.9) |  | Female | 7 | 6.3 | 110.8 | (44.4-228.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 6 | 8.2 | 72.9 | (26.6-158.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 17.1 | 58.5 | (28.0-107.6) |  | Male | 110 | 122.9 | 89.5 | (73.6-107.9) |
| Female | 13 | 18.2 | 71.4 | (38.0-122.0) |  | Female | 131 | 124.4 | 105.3 | (88.0-124.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

75

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 10 | 7.8 | 128.7 | (61.6-236.7) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 7.5 | 66.5 | (21.4-155.2) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 5 | 1.8 | 276.0 | (89.0-644.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 22 | 31.3 | 70.3 | (44.1-106.5) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 31 | 25.6 | 120.9 | (82.1-171.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

76

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 26.5 | 113.3 | (76.4-161.8) |  | Male | 22 | 16.3 | 134.6 | (84.3-203.8) |
| Female | 10 | 9.3 | 107.4 | (51.4-197.5) |  | Female | 25 | 11.3 | 220.5 | (142.6-325.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.7 | 106.6 | (34.4-248.8) |  | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 13 | 14.7 | 88.5 | (47.1-151.4) |
| Female | 122 | 94.1 | 129.6 | (107.7-154.8) |  | Female | 9 | 12.5 | 72.1 | (32.9-136.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 12.1 | 82.8 | (39.6-152.3) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 7 | 5.2 | 134.2 | (53.8-276.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 28.3 | 67.2 | (40.5-105.0) |  |  |  |  |  |  |
| Female | 35 | 27.1 | 129.4 | (90.1-179.9) |  | Female | 14 | 8.2 | 171.1 | (93.4-287.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 6.7 | nc | (nc-nc) |  | Male | 8 | 9.3 | 86.1 | (37.1-169.7) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 7 | 9.6 | 73.0 | (29.3-150.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 87 | 80.1 | 108.6 | (87.0-133.9) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 14.2 | 56.2 | (24.2-110.8) |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 11 | 7.6 | 144.6 | (72.1-258.7) |  | Female | 0 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 10.3 | 67.9 | (27.2-139.9) |  | Male | 5 | 6.2 | 81.2 | (26.2-189.4) |
| Female | 4 | 7.1 | nc | (nc-nc) |  | Female | 15 | 14.5 | 103.6 | (58.0-170.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 8.9 | 89.5 | (38.6-176.4) |  |  |  |  |  |  |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 23 | 21.2 | 108.6 | (68.8-163.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 46.3 | 47.5 | (29.8-71.9) |  | Male | 286 | 332.5 | 86.0 | (76.3-96.6) |
| Female | 27 | 47.0 | 57.4 | (37.8-83.5) |  | Female | 357 | 323.7 | 110.3 | (99.1-122.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

77

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 7 | 9.7 | 72.4 | (29.0-149.2) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 8.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 28 | 30.1 | 93.1 | (61.9-134.6) |
| Female | 1 | 4.1 | nc | (nc-nc) |  | Female | 21 | 30.3 | 69.3 | (42.9-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

78

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 9 | 5.1 | 177.3 | (80.9-336.7) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 14 | 17.7 | 79.0 | (43.1-132.5) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 21 | 17.3 | 121.6 | (75.2-185.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

79

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 9.9 | 70.9 | (28.4-146.0) |  | Male | 10 | 5.9 | 169.6 | (81.2-311.9) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 26 | 35.6 | 73.0 | (47.7-107.0) |  | Female | 2 | 4.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 10.2 | 88.7 | (40.5-168.3) |  |  |  |  |  |  |
| Female | 9 | 10.1 | 89.1 | (40.6-169.1) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 30 | 26.8 | 112.0 | (75.5-159.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 1 | 5.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 10 | 8.0 | 124.9 | (59.8-229.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 17.3 | 81.0 | (44.2-135.9) |  | Male | 100 | 118.1 | 84.7 | (68.9-103.0) |
| Female | 18 | 18.4 | 97.6 | (57.8-154.3) |  | Female | 97 | 123.0 | 78.8 | (63.9-96.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

80

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 35.4 | 101.6 | (71.2-140.7) |  | Male | 18 | 21.7 | 83.1 | (49.2-131.3) |
| Female | 11 | 12.8 | 85.7 | (42.7-153.4) |  | Female | 12 | 16.1 | 74.7 | (38.6-130.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 6.2 | 176.3 | (87.9-315.5) |  | Male | 3 | 7.0 | nc | (nc-nc) |
| Female | 5 | 5.1 | 97.4 | (31.4-227.4) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 15 | 19.4 | 77.4 | (43.3-127.7) |
| Female | 138 | 129.3 | 106.7 | (89.6-126.1) |  | Female | 25 | 17.3 | 144.9 | (93.7-213.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 15.5 | 103.1 | (58.9-167.4) |
| Female | 4 | 4.0 | nc | (nc-nc) |  | Female | 8 | 7.1 | 112.4 | (48.4-221.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 36.9 | 92.1 | (63.8-128.7) |  |  |  |  |  |  |
| Female | 37 | 37.2 | 99.5 | (70.1-137.2) |  | Female | 13 | 11.3 | 115.5 | (61.4-197.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 8.7 | 115.0 | (55.0-211.4) |  | Male | 12 | 12.4 | 97.1 | (50.1-169.7) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 14 | 13.2 | 106.4 | (58.1-178.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 104 | 101.2 | 102.7 | (83.9-124.5) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 18.3 | 114.8 | (71.0-175.5) |  | Male | 5 | 8.3 | 59.9 | (19.3-139.8) |
| Female | 12 | 10.5 | 114.5 | (59.1-200.0) |  | Female | 5 | 5.1 | 98.0 | (31.6-228.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 7 | 3.8 | 183.7 | (73.6-378.6) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 13.8 | 86.8 | (44.8-151.6) |  | Male | 11 | 7.9 | 138.4 | (69.0-247.7) |
| Female | 15 | 10.0 | 149.6 | (83.7-246.8) |  | Female | 30 | 21.7 | 138.0 | (93.1-197.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 11.5 | 69.7 | (30.0-137.3) |  |  |  |  |  |  |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 42 | 28.5 | 147.6 | (106.3-199.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 66 | 61.8 | 106.8 | (82.6-135.9) |  | Male | 434 | 434.8 | 99.8 | (90.7-109.7) |
| Female | 54 | 64.8 | 83.4 | (62.6-108.8) |  | Female | 479 | 447.9 | 107.0 | (97.6-117.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

81

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 57 | 41.2 | 138.3 | (104.7-179.2) |  | Male | 24 | 25.1 | 95.6 | (61.2-142.3) |
| Female | 18 | 15.0 | 120.0 | (71.1-189.7) |  | Female | 14 | 19.0 | 73.6 | (40.2-123.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 7.4 | 67.3 | (21.7-157.0) |  | Male | 5 | 8.1 | 61.9 | (19.9-144.4) |
| Female | 6 | 6.1 | 98.4 | (35.9-214.2) |  | Female | 4 | 6.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 23 | 22.7 | 101.2 | (64.1-151.8) |
| Female | 129 | 151.4 | 85.2 | (71.1-101.2) |  | Female | 15 | 20.2 | 74.1 | (41.4-122.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 18.0 | 94.4 | (55.0-151.2) |
| Female | 5 | 4.7 | 106.2 | (34.2-247.9) |  | Female | 10 | 8.5 | 117.9 | (56.5-216.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 43.2 | 90.2 | (64.1-123.3) |  |  |  |  |  |  |
| Female | 50 | 43.7 | 114.4 | (84.9-150.8) |  | Female | 8 | 13.3 | 60.0 | (25.8-118.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 10.1 | 109.0 | (54.4-195.1) |  | Male | 13 | 14.2 | 91.2 | (48.5-156.0) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 8 | 15.7 | 51.1 | (22.0-100.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 142 | 118.4 | 119.9 | (101.0-141.3) |
| Female | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 21.2 | 99.1 | (61.3-151.5) |  | Male | 15 | 9.7 | 155.1 | (86.8-255.9) |
| Female | 18 | 12.2 | 147.1 | (87.1-232.5) |  | Female | 11 | 6.0 | 183.9 | (91.7-329.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 5.7 | 122.0 | (48.9-251.3) |  | Male | 6 | 5.5 | 109.6 | (40.0-238.5) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 16.2 | 86.2 | (47.1-144.6) |  | Male | 7 | 9.4 | 74.2 | (29.7-152.9) |
| Female | 8 | 11.7 | 68.3 | (29.4-134.6) |  | Female | 33 | 26.0 | 126.9 | (87.3-178.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 13.3 | 90.4 | (46.7-158.0) |  |  |  |  |  |  |
| Female | 1 | 4.7 | nc | (nc-nc) |  | Female | 32 | 33.9 | 94.3 | (64.5-133.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 71 | 71.1 | 99.9 | (78.0-126.0) |  | Male | 517 | 507.9 | 101.8 | (93.2-111.0) |
| Female | 42 | 75.5 | 55.6 | (40.1-75.2) |  | Female | 450 | 526.7 | 85.4 | (77.7-93.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

82

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 30.5 | 95.0 | (63.6-136.4) |  | Male | 24 | 18.6 | 128.9 | (82.6-191.8) |
| Female | 12 | 12.7 | 94.2 | (48.6-164.6) |  | Female | 19 | 15.5 | 122.4 | (73.6-191.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 5.5 | 145.7 | (62.7-287.0) |  | Male | 9 | 6.0 | 149.0 | (68.0-283.0) |
| Female | 5 | 4.9 | 102.4 | (33.0-239.1) |  | Female | 2 | 5.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 23 | 16.9 | 136.1 | (86.3-204.3) |
| Female | 155 | 123.4 | 125.7 | (106.6-147.1) |  | Female | 16 | 16.9 | 94.9 | (54.2-154.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 13.1 | 122.5 | (69.9-198.9) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 12 | 6.9 | 173.8 | (89.7-303.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 32.0 | 96.8 | (65.8-137.4) |  |  |  |  |  |  |
| Female | 28 | 36.9 | 75.9 | (50.4-109.6) |  | Female | 9 | 10.8 | 83.2 | (38.0-158.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.4 | nc | (nc-nc) |  | Male | 14 | 10.5 | 132.7 | (72.5-222.7) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 18 | 13.0 | 138.0 | (81.7-218.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 89 | 85.6 | 104.0 | (83.5-128.0) |
| Female | 5 | 1.7 | 288.0 | (92.8-672.0) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 15.8 | 126.8 | (77.4-195.9) |  | Male | 6 | 7.2 | 83.4 | (30.5-181.6) |
| Female | 11 | 10.1 | 108.5 | (54.1-194.2) |  | Female | 8 | 5.1 | 157.9 | (68.0-311.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 12.1 | 99.4 | (51.3-173.6) |  | Male | 6 | 7.1 | 84.8 | (31.0-184.7) |
| Female | 9 | 9.8 | 91.6 | (41.8-174.0) |  | Female | 29 | 20.6 | 140.7 | (94.2-202.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 9.5 | 115.4 | (57.5-206.5) |  |  |  |  |  |  |
| Female | 6 | 3.9 | 152.5 | (55.7-331.9) |  | Female | 27 | 26.8 | 100.8 | (66.4-146.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 52 | 52.4 | 99.2 | (74.1-130.1) |  | Male | 405 | 373.1 | 108.6 | (98.2-119.7) |
| Female | 79 | 63.8 | 123.9 | (98.1-154.4) |  | Female | 486 | 434.2 | 111.9 | (102.2-122.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

83

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 5 | 3.2 | 157.6 | (50.8-367.8) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 6 | 3.1 | 195.0 | (71.2-424.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 21 | 25.5 | 82.2 | (50.9-125.7) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.4 | 111.7 | (40.8-243.1) |  |  |  |  |  |  |
| Female | 6 | 6.3 | 94.6 | (34.6-206.0) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 14 | 16.8 | 83.6 | (45.6-140.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 3.0 | 164.4 | (53.0-383.7) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 8 | 5.7 | 139.4 | (60.0-274.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 8.1 | nc | (nc-nc) |  | Male | 55 | 64.5 | 85.3 | (64.3-111.1) |
| Female | 7 | 11.7 | 60.0 | (24.0-123.6) |  | Female | 72 | 83.6 | 86.1 | (67.4-108.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

84

# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 50 | 29.3 | 170.6 | (126.6-224.9) |  | Male | 36 | 16.2 | 222.3 | (155.7-307.8) |
| Female | 15 | 10.9 | 137.4 | (76.8-226.6) |  | Female | 22 | 11.7 | 187.4 | (117.4-283.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 11 | 5.4 | 202.2 | (100.8-361.8) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 1 | 4.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 14 | 14.4 | 97.0 | (53.0-162.7) |
| Female | 109 | 100.6 | 108.3 | (89.0-130.7) |  | Female | 11 | 13.8 | 79.5 | (39.6-142.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 10.5 | 151.8 | (86.7-246.5) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 4 | 5.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 27.4 | 91.2 | (59.0-134.7) |  |  |  |  |  |  |
| Female | 26 | 28.6 | 91.0 | (59.4-133.3) |  | Female | 15 | 8.8 | 170.6 | (95.4-281.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 6.8 | 206.5 | (112.8-346.5) |  | Male | 12 | 9.7 | 123.9 | (64.0-216.5) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 13 | 10.8 | 120.0 | (63.8-205.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 100 | 78.8 | 126.9 | (103.2-154.3) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 13.1 | 61.3 | (26.4-120.8) |  | Male | 2 | 6.6 | nc | (nc-nc) |
| Female | 5 | 8.6 | 58.1 | (18.7-135.6) |  | Female | 2 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 10.3 | 116.0 | (59.9-202.6) |  | Male | 2 | 4.6 | nc | (nc-nc) |
| Female | 6 | 7.6 | 79.3 | (29.0-172.6) |  | Female | 15 | 13.4 | 111.8 | (62.5-184.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 8.3 | 96.6 | (41.6-190.3) |  |  |  |  |  |  |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 17 | 23.4 | 72.7 | (42.3-116.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 45 | 51.7 | 87.1 | (63.5-116.5) |  | Male | 396 | 332.8 | 119.0 | (107.6-131.3) |
| Female | 58 | 58.6 | 98.9 | (75.1-127.9) |  | Female | 363 | 355.1 | 102.2 | (92.0-113.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

85

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 8.8 | 113.9 | (54.5-209.4) |  | Male | 7 | 5.5 | 128.1 | (51.3-263.9) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 4.8 | 103.2 | (33.2-240.7) |
| Female | 19 | 28.2 | 67.3 | (40.5-105.0) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 9.4 | 137.8 | (73.3-235.7) |  |  |  |  |  |  |
| Female | 5 | 7.5 | 66.7 | (21.5-155.7) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 22 | 25.4 | 86.7 | (54.3-131.2) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.6 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 5 | 2.3 | 220.7 | (71.1-515.1) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 4 | 5.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 7 | 6.2 | 113.4 | (45.4-233.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 15.4 | 51.9 | (22.4-102.3) |  | Male | 102 | 109.6 | 93.1 | (75.9-113.0) |
| Female | 14 | 13.4 | 104.3 | (57.0-175.1) |  | Female | 79 | 95.2 | 83.0 | (65.7-103.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

86

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.7 | 90.3 | (36.2-186.1) |  | Male | 9 | 5.4 | 166.2 | (75.8-315.5) |
| Female | 5 | 2.0 | 248.5 | (80.1-580.0) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 33 | 31.3 | 105.4 | (72.6-148.1) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.3 | 116.3 | (37.5-271.5) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 9.0 | 66.8 | (24.4-145.5) |  |  |  |  |  |  |
| Female | 8 | 6.3 | 126.7 | (54.6-249.7) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 24 | 27.4 | 87.4 | (56.0-130.1) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 4.9 | 182.6 | (83.3-346.7) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 5 | 2.4 | 208.5 | (67.2-486.5) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 8 | 6.6 | 121.4 | (52.3-239.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 9 | 7.1 | 126.4 | (57.7-240.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 14.4 | 96.9 | (52.9-162.6) |  | Male | 111 | 109.7 | 101.2 | (83.2-121.8) |
| Female | 14 | 11.7 | 119.3 | (65.1-200.1) |  | Female | 105 | 95.0 | 110.6 | (90.4-133.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

87

# Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 7.7 | nc | (nc-nc) |  | Male | 11 | 5.4 | 203.1 | (101.3-363.5) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.9 | 144.0 | (57.7-296.7) |
| Female | 28 | 25.6 | 109.2 | (72.5-157.8) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 9.0 | 78.0 | (31.2-160.7) |  |  |  |  |  |  |
| Female | 3 | 6.0 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 23 | 27.4 | 83.8 | (53.1-125.8) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 5 | 2.4 | 208.5 | (67.2-486.5) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 5 | 4.5 | 111.8 | (36.0-261.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 5.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 14.4 | 62.3 | (28.4-118.3) |  | Male | 91 | 109.7 | 82.9 | (66.8-101.8) |
| Female | 7 | 11.3 | 62.1 | (24.9-127.9) |  | Female | 66 | 81.4 | 81.0 | (62.7-103.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

88

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 40 | 29.8 | 134.3 | (95.9-182.8) |  | Male | 13 | 19.9 | 65.4 | (34.8-111.8) |
| Female | 20 | 10.5 | 190.5 | (116.3-294.2) |  | Female | 15 | 15.7 | 95.8 | (53.6-158.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 6.4 | 125.2 | (53.9-246.8) |  | Male | 7 | 6.3 | 111.0 | (44.5-228.8) |
| Female | 5 | 5.0 | 100.1 | (32.3-233.7) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 14 | 17.7 | 79.2 | (43.2-132.8) |
| Female | 135 | 126.9 | 106.4 | (89.2-125.9) |  | Female | 14 | 15.2 | 91.9 | (50.2-154.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 15.6 | 64.2 | (30.8-118.1) |
| Female | 6 | 4.4 | 135.5 | (49.5-295.0) |  | Female | 10 | 6.5 | 154.1 | (73.8-283.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 40 | 33.1 | 120.8 | (86.3-164.4) |  |  |  |  |  |  |
| Female | 44 | 30.9 | 142.2 | (103.3-191.0) |  | Female | 11 | 10.8 | 102.1 | (50.9-182.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 8.1 | 159.6 | (84.9-272.9) |  | Male | 9 | 10.9 | 82.3 | (37.5-156.2) |
| Female | 5 | 2.1 | 239.3 | (77.1-558.4) |  | Female | 14 | 10.5 | 133.0 | (72.6-223.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 96 | 103.1 | 93.1 | (75.4-113.7) |
| Female | 2 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 18.0 | 116.5 | (72.1-178.1) |  | Male | 11 | 7.4 | 149.5 | (74.5-267.6) |
| Female | 14 | 9.9 | 141.3 | (77.2-237.1) |  | Female | 5 | 4.2 | 119.2 | (38.4-278.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 4.8 | 167.7 | (72.2-330.5) |  | Male | 5 | 4.7 | 107.5 | (34.6-250.9) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 12.7 | 142.0 | (84.1-224.4) |  | Male | 5 | 8.4 | 59.8 | (19.3-139.5) |
| Female | 9 | 8.8 | 102.1 | (46.6-193.9) |  | Female | 23 | 24.6 | 93.5 | (59.2-140.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 11.3 | 88.2 | (42.2-162.2) |  |  |  |  |  |  |
| Female | 5 | 3.6 | 139.0 | (44.8-324.5) |  | Female | 21 | 28.4 | 73.9 | (45.7-113.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 64 | 54.8 | 116.7 | (89.9-149.0) |  | Male | 441 | 407.9 | 108.1 | (98.3-118.7) |
| Female | 73 | 56.8 | 128.6 | (100.8-161.7) |  | Female | 480 | 415.0 | 115.7 | (105.5-126.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

89

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 11.1 | 99.3 | (49.5-177.7) |  | Male | 6 | 7.2 | 83.0 | (30.3-180.8) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 5 | 5.0 | 100.3 | (32.3-234.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 4 | 6.6 | nc | (nc-nc) |
| Female | 45 | 40.7 | 110.6 | (80.7-148.0) |  | Female | 5 | 4.7 | 106.3 | (34.3-248.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.2 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 12.0 | 108.6 | (57.8-185.8) |  |  |  |  |  |  |
| Female | 11 | 9.5 | 115.6 | (57.6-206.9) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 5 | 4.0 | 126.3 | (40.7-294.7) |
| Female | 3 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 34 | 33.0 | 102.9 | (71.2-143.8) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 6.2 | 177.3 | (88.4-317.2) |  | Male | 5 | 2.7 | 185.1 | (59.6-431.9) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 4.7 | 212.9 | (101.9-391.6) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 5 | 2.7 | 181.9 | (58.6-424.4) |  | Female | 11 | 8.3 | 132.2 | (65.9-236.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 17 | 9.0 | 188.6 | (109.8-302.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 19.7 | 126.7 | (82.0-187.0) |  | Male | 155 | 143.7 | 107.9 | (91.6-126.3) |
| Female | 24 | 17.0 | 141.2 | (90.4-210.1) |  | Female | 167 | 130.5 | 128.0 | (109.3-148.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

90

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 15 | 15.1 | 99.4 | (55.6-164.0) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 3.5 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 11.9 | 84.0 | (40.2-154.5) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 3 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 5 | 3.4 | 147.8 | (47.6-345.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.9 | nc | (nc-nc) |  | Male | 41 | 45.1 | 90.9 | (65.2-123.3) |
| Female | 9 | 6.0 | 151.3 | (69.0-287.2) |  | Female | 45 | 47.3 | 95.1 | (69.4-127.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

91

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 18.6 | 140.0 | (91.4-205.1) |  | Male | 30 | 11.5 | 260.2 | (175.5-371.5) |
| Female | 2 | 6.3 | nc | (nc-nc) |  | Female | 13 | 8.6 | 151.6 | (80.6-259.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.5 | 144.6 | (46.6-337.5) |  | Male | 9 | 3.9 | 233.8 | (106.7-443.8) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 18 | 10.5 | 172.1 | (101.9-272.0) |
| Female | 86 | 72.7 | 118.3 | (94.6-146.1) |  | Female | 6 | 8.9 | 67.6 | (24.7-147.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.8 | 56.7 | (18.3-132.3) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 20.0 | 49.9 | (23.9-91.7) |  |  |  |  |  |  |
| Female | 11 | 18.9 | 58.3 | (29.1-104.4) |  | Female | 8 | 6.2 | 129.7 | (55.8-255.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 5 | 6.6 | 75.4 | (24.3-176.1) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 7 | 6.5 | 107.8 | (43.2-222.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 81 | 59.6 | 135.9 | (107.9-168.9) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 10.4 | 144.9 | (81.1-239.0) |  | Male | 1 | 4.5 | nc | (nc-nc) |
| Female | 2 | 5.6 | nc | (nc-nc) |  | Female | 0 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.4 | 94.3 | (37.8-194.2) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 6 | 5.0 | 119.0 | (43.5-259.1) |  | Female | 8 | 12.4 | 64.6 | (27.8-127.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 9 | 16.1 | 55.9 | (25.5-106.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 32.9 | 78.9 | (51.5-115.7) |  | Male | 266 | 239.1 | 111.3 | (98.3-125.5) |
| Female | 21 | 33.0 | 63.7 | (39.4-97.3) |  | Female | 212 | 238.6 | 88.9 | (77.3-101.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

92

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 13.5 | 103.4 | (56.5-173.5) |  | Male | 12 | 9.0 | 132.6 | (68.4-231.6) |
| Female | 3 | 5.9 | nc | (nc-nc) |  | Female | 9 | 8.1 | 111.5 | (50.9-211.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 10 | 8.1 | 123.2 | (59.0-226.5) |
| Female | 45 | 67.6 | 66.6 | (48.6-89.1) |  | Female | 11 | 8.3 | 132.7 | (66.2-237.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 7.0 | 128.9 | (58.8-244.6) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 15.2 | 138.3 | (85.6-211.4) |  |  |  |  |  |  |
| Female | 10 | 17.0 | 58.8 | (28.1-108.1) |  | Female | 7 | 5.8 | 121.7 | (48.8-250.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.6 | 137.3 | (44.2-320.3) |  | Male | 3 | 5.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 7 | 6.0 | 116.8 | (46.8-240.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 50 | 45.1 | 110.8 | (82.3-146.1) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 8.2 | 158.6 | (84.3-271.2) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 5 | 5.3 | 93.8 | (30.2-218.9) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 4 | 4.7 | nc | (nc-nc) |  | Female | 11 | 11.9 | 92.3 | (46.0-165.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.0 | 100.4 | (32.4-234.4) |  |  |  |  |  |  |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 11 | 15.3 | 71.8 | (35.8-128.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 24.9 | 104.4 | (68.2-153.0) |  | Male | 198 | 183.4 | 108.0 | (93.5-124.1) |
| Female | 26 | 32.0 | 81.3 | (53.1-119.1) |  | Female | 178 | 223.6 | 79.6 | (68.4-92.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

93

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 5 | 10.6 | 47.2 | (15.2-110.2) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 9.0 | 111.2 | (53.2-204.5) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 34 | 36.2 | 94.0 | (65.1-131.4) |
| Female | 6 | 4.6 | 131.5 | (48.0-286.2) |  | Female | 25 | 33.7 | 74.3 | (48.0-109.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

94

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 20.8 | 77.0 | (44.0-125.0) |  | Male | 18 | 12.6 | 143.3 | (84.9-226.5) |
| Female | 5 | 8.4 | 59.5 | (19.2-138.9) |  | Female | 9 | 10.2 | 88.5 | (40.4-168.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 10 | 11.3 | 88.2 | (42.2-162.2) |
| Female | 83 | 81.7 | 101.6 | (80.9-125.9) |  | Female | 7 | 11.2 | 62.5 | (25.0-128.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 9.1 | 87.6 | (37.7-172.6) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 21.8 | 110.0 | (70.4-163.6) |  |  |  |  |  |  |
| Female | 32 | 24.3 | 131.5 | (89.9-185.6) |  | Female | 14 | 7.2 | 194.6 | (106.3-326.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 6 | 7.2 | 83.0 | (30.3-180.6) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 10 | 8.6 | 116.2 | (55.6-213.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 51 | 61.6 | 82.8 | (61.7-108.9) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 10.8 | 139.1 | (77.8-229.4) |  | Male | 6 | 4.9 | 122.6 | (44.8-266.9) |
| Female | 5 | 6.7 | 74.5 | (24.0-173.7) |  | Female | 6 | 3.4 | 178.9 | (65.3-389.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 8.0 | 62.4 | (20.1-145.7) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 2 | 6.5 | nc | (nc-nc) |  | Female | 12 | 13.3 | 90.6 | (46.7-158.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 6.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 17 | 18.1 | 94.1 | (54.8-150.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 36.1 | 102.5 | (72.2-141.3) |  | Male | 234 | 256.5 | 91.2 | (79.9-103.7) |
| Female | 52 | 42.3 | 123.0 | (91.9-161.3) |  | Female | 290 | 287.1 | 101.0 | (89.7-113.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

95

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 11.2 | 98.0 | (48.9-175.4) |  | Male | 7 | 6.3 | 111.9 | (44.8-230.5) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 12 | 4.0 | 300.8 | (155.2-525.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 5.5 | 90.3 | (29.1-210.6) |
| Female | 52 | 34.2 | 152.2 | (113.6-199.6) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.4 | 135.5 | (49.5-294.8) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 10.8 | 92.8 | (44.4-170.7) |  |  |  |  |  |  |
| Female | 11 | 9.4 | 117.1 | (58.4-209.6) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 5 | 3.5 | 142.3 | (45.8-332.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 40 | 33.1 | 120.8 | (86.3-164.5) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 5.3 | 114.2 | (41.7-248.7) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 4.0 | 201.3 | (86.7-396.7) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 3 | 4.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 4 | 8.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 19.6 | 117.1 | (74.2-175.7) |  | Male | 149 | 131.6 | 113.3 | (95.8-133.0) |
| Female | 12 | 18.8 | 63.8 | (32.9-111.4) |  | Female | 133 | 118.3 | 112.4 | (94.1-133.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

96

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 17.9 | 72.7 | (38.7-124.3) |  | Male | 8 | 11.9 | 67.4 | (29.0-132.7) |
| Female | 3 | 7.2 | nc | (nc-nc) |  | Female | 7 | 9.8 | 71.6 | (28.7-147.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.6 | 140.4 | (45.2-327.6) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 13 | 10.5 | 123.2 | (65.6-210.8) |
| Female | 76 | 77.8 | 97.7 | (77.0-122.3) |  | Female | 9 | 10.0 | 90.1 | (41.1-171.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 9.2 | 119.5 | (59.6-213.9) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 5 | 4.2 | 119.4 | (38.5-278.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 19.9 | 145.4 | (97.4-208.8) |  |  |  |  |  |  |
| Female | 22 | 21.1 | 104.4 | (65.4-158.1) |  | Female | 1 | 6.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.8 | nc | (nc-nc) |  | Male | 4 | 6.6 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 11 | 7.2 | 151.9 | (75.7-271.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 49 | 60.2 | 81.4 | (60.2-107.7) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.6 | 94.4 | (45.2-173.6) |  | Male | 5 | 4.4 | 112.6 | (36.3-262.8) |
| Female | 8 | 6.2 | 128.7 | (55.4-253.6) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 7.3 | nc | (nc-nc) |  | Male | 0 | 4.9 | nc | (nc-nc) |
| Female | 3 | 5.6 | nc | (nc-nc) |  | Female | 7 | 14.3 | 48.9 | (19.6-100.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 19 | 17.4 | 109.2 | (65.7-170.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 32.6 | 89.1 | (59.6-127.9) |  | Male | 203 | 241.0 | 84.2 | (73.0-96.6) |
| Female | 35 | 37.4 | 93.6 | (65.2-130.1) |  | Female | 238 | 263.9 | 90.2 | (79.1-102.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

97

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 21.0 | 128.3 | (84.5-186.7) |  | Male | 20 | 14.3 | 140.0 | (85.5-216.3) |
| Female | 11 | 7.0 | 156.8 | (78.2-280.6) |  | Female | 14 | 10.9 | 128.3 | (70.1-215.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.7 | 128.3 | (46.9-279.3) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 5 | 3.3 | 150.8 | (48.6-351.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 12 | 12.9 | 93.2 | (48.1-162.8) |
| Female | 110 | 88.9 | 123.8 | (101.7-149.2) |  | Female | 9 | 10.5 | 85.9 | (39.2-163.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 11.4 | 79.0 | (36.0-150.0) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 23.9 | 50.1 | (25.9-87.6) |  |  |  |  |  |  |
| Female | 30 | 20.9 | 143.6 | (96.9-205.1) |  | Female | 9 | 7.5 | 119.8 | (54.7-227.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.9 | nc | (nc-nc) |  | Male | 12 | 7.8 | 153.4 | (79.2-267.9) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 8 | 7.1 | 113.5 | (48.9-223.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 87 | 74.9 | 116.1 | (93.0-143.3) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 13.2 | 98.4 | (52.4-168.4) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 4 | 6.8 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 9.1 | 164.2 | (91.9-270.9) |  | Male | 10 | 6.2 | 160.7 | (76.9-295.5) |
| Female | 4 | 6.1 | nc | (nc-nc) |  | Female | 19 | 17.8 | 107.0 | (64.4-167.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 8.2 | 158.6 | (84.3-271.2) |  |  |  |  |  |  |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 17 | 19.9 | 85.4 | (49.7-136.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 39.1 | 102.4 | (73.1-139.4) |  | Male | 317 | 294.6 | 107.6 | (96.1-120.1) |
| Female | 49 | 38.1 | 128.7 | (95.2-170.2) |  | Female | 339 | 287.0 | 118.1 | (105.9-131.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

98

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 7.0 | 100.6 | (40.3-207.4) |  | Male | 17 | 4.5 | 378.0 | (220.1-605.3) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 24 | 17.7 | 135.9 | (87.0-202.2) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 7.6 | 132.2 | (63.3-243.1) |  |  |  |  |  |  |
| Female | 4 | 4.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 24 | 25.5 | 94.1 | (60.3-140.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 4.2 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 6 | 3.0 | 197.8 | (72.2-430.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 4.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 12.6 | 79.5 | (38.0-146.2) |  | Male | 91 | 95.0 | 95.8 | (77.1-117.6) |
| Female | 10 | 8.2 | 121.2 | (58.0-222.9) |  | Female | 64 | 58.6 | 109.1 | (84.0-139.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

99

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 6 | 7.2 | 83.4 | (30.5-181.6) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 2.5 | 202.0 | (65.1-471.4) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 7.8 | 77.0 | (28.1-167.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 4.4 | nc | (nc-nc) |  | Male | 23 | 30.4 | 75.7 | (48.0-113.6) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 22 | 25.3 | 86.9 | (54.4-131.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

100

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 6 | 7.7 | 77.6 | (28.4-169.0) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 6.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 15 | 24.7 | 60.8 | (34.0-100.3) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 21 | 25.6 | 81.9 | (50.7-125.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

101

# Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 4.5 | 155.3 | (62.2-320.0) |  | Male | 8 | 2.9 | 276.8 | (119.2-545.4) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 3 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 13 | 16.5 | 78.7 | (41.8-134.5) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 2.2 | 222.3 | (71.6-518.8) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 4.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 15.3 | 52.4 | (22.5-103.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 8.2 | 134.8 | (67.2-241.2) |  | Male | 62 | 59.9 | 103.6 | (79.4-132.8) |
| Female | 8 | 7.1 | 112.7 | (48.5-222.0) |  | Female | 49 | 52.6 | 93.2 | (69.0-123.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

102

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 33 | 36.5 | 90.3 | (62.2-126.8) |  | Male | 18 | 24.4 | 73.6 | (43.6-116.4) |
| Female | 12 | 13.2 | 90.8 | (46.9-158.6) |  | Female | 7 | 20.5 | 34.1 | (13.7-70.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 8.1 | nc | (nc-nc) |  | Male | 9 | 7.6 | 118.3 | (54.0-224.6) |
| Female | 2 | 6.5 | nc | (nc-nc) |  | Female | 2 | 6.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 17 | 21.9 | 77.8 | (45.3-124.5) |
| Female | 139 | 157.3 | 88.4 | (74.3-104.3) |  | Female | 19 | 19.3 | 98.2 | (59.1-153.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 17.9 | 111.4 | (68.0-172.1) |
| Female | 16 | 6.1 | 264.3 | (151.0-429.3) |  | Female | 10 | 8.1 | 123.4 | (59.1-226.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 40.6 | 96.0 | (68.2-131.2) |  |  |  |  |  |  |
| Female | 30 | 40.9 | 73.3 | (49.4-104.6) |  | Female | 11 | 13.4 | 82.1 | (40.9-147.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 9.4 | 148.6 | (81.1-249.3) |  | Male | 9 | 13.0 | 69.0 | (31.5-131.1) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 15 | 13.5 | 110.9 | (62.0-182.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 97 | 110.9 | 87.4 | (70.9-106.7) |
| Female | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 28 | 21.3 | 131.4 | (87.3-189.9) |  | Male | 17 | 9.0 | 189.6 | (110.4-303.5) |
| Female | 17 | 12.2 | 139.6 | (81.3-223.5) |  | Female | 6 | 5.6 | 108.1 | (39.5-235.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.5 | 109.0 | (39.8-237.3) |  | Male | 5 | 7.3 | 68.9 | (22.2-160.7) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 15.9 | 94.5 | (52.8-155.9) |  | Male | 12 | 10.7 | 112.5 | (58.1-196.6) |
| Female | 11 | 11.6 | 94.9 | (47.3-169.8) |  | Female | 27 | 33.8 | 79.8 | (52.6-116.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 20 | 12.9 | 155.0 | (94.6-239.4) |  |  |  |  |  |  |
| Female | 6 | 4.4 | 137.9 | (50.4-300.2) |  | Female | 27 | 33.2 | 81.4 | (53.7-118.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 71 | 65.8 | 107.8 | (84.2-136.0) |  | Male | 467 | 483.4 | 96.6 | (88.0-105.8) |
| Female | 84 | 68.4 | 122.8 | (98.0-152.1) |  | Female | 485 | 523.1 | 92.7 | (84.6-101.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

103

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 21.1 | 108.9 | (69.0-163.4) |  | Male | 5 | 13.0 | 38.5 | (12.4-89.9) |
| Female | 18 | 8.6 | 209.4 | (124.1-331.0) |  | Female | 7 | 10.6 | 65.9 | (26.4-135.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 5 | 4.2 | 118.3 | (38.1-276.2) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 9 | 11.6 | 77.3 | (35.3-146.7) |
| Female | 79 | 84.6 | 93.4 | (73.9-116.4) |  | Female | 15 | 11.5 | 131.0 | (73.2-216.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 9.7 | 72.4 | (29.0-149.1) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 2 | 4.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 22.3 | 44.9 | (21.5-82.5) |  |  |  |  |  |  |
| Female | 19 | 24.9 | 76.4 | (46.0-119.4) |  | Female | 14 | 7.5 | 187.3 | (102.3-314.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 6 | 7.5 | 80.4 | (29.3-174.9) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 9 | 8.9 | 101.5 | (46.3-192.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 60 | 66.7 | 90.0 | (68.6-115.8) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 11.3 | 149.9 | (87.3-240.1) |  | Male | 5 | 5.0 | 99.9 | (32.2-233.1) |
| Female | 8 | 7.0 | 115.0 | (49.5-226.7) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 4 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.1 | 85.9 | (34.4-177.0) |  | Male | 2 | 4.8 | nc | (nc-nc) |
| Female | 11 | 6.6 | 165.7 | (82.6-296.5) |  | Female | 12 | 14.0 | 85.6 | (44.2-149.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 7.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 19 | 19.0 | 99.8 | (60.0-155.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 37.1 | 113.1 | (81.5-152.9) |  | Male | 236 | 267.2 | 88.3 | (77.4-100.3) |
| Female | 39 | 43.3 | 90.0 | (64.0-123.1) |  | Female | 289 | 296.5 | 97.5 | (86.6-109.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

104

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 101 | 85.8 | 117.7 | (95.9-143.0) |  | Male | 31 | 55.2 | 56.2 | (38.2-79.8) |
| Female | 39 | 37.8 | 103.2 | (73.4-141.0) |  | Female | 25 | 50.3 | 49.7 | (32.1-73.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 18 | 17.3 | 103.8 | (61.5-164.1) |  | Male | 12 | 17.5 | 68.5 | (35.3-119.6) |
| Female | 10 | 16.1 | 62.2 | (29.8-114.4) |  | Female | 16 | 16.9 | 94.4 | (53.9-153.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 42 | 49.7 | 84.5 | (60.9-114.2) |
| Female | 328 | 395.2 | 83.0 | (74.3-92.5) |  | Female | 49 | 52.0 | 94.2 | (69.7-124.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 41 | 40.9 | 100.3 | (71.9-136.0) |
| Female | 17 | 13.2 | 128.4 | (74.7-205.5) |  | Female | 18 | 21.6 | 83.5 | (49.4-131.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 109 | 93.2 | 117.0 | (96.0-141.1) |  |  |  |  |  |  |
| Female | 112 | 110.6 | 101.3 | (83.4-121.9) |  | Female | 16 | 34.5 | 46.4 | (26.5-75.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 21 | 22.1 | 95.2 | (58.9-145.5) |  | Male | 30 | 30.7 | 97.8 | (66.0-139.7) |
| Female | 4 | 7.3 | nc | (nc-nc) |  | Female | 49 | 38.7 | 126.7 | (93.7-167.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 10 | 7.3 | 137.0 | (65.6-252.0) |  | Male | 291 | 269.6 | 107.9 | (95.9-121.1) |
| Female | 7 | 6.4 | 108.9 | (43.6-224.3) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 50 | 48.3 | 103.5 | (76.8-136.4) |  | Male | 30 | 20.7 | 144.6 | (97.5-206.5) |
| Female | 32 | 31.9 | 100.2 | (68.5-141.5) |  | Female | 26 | 15.1 | 172.4 | (112.6-252.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 20 | 12.8 | 156.3 | (95.4-241.4) |  | Male | 10 | 13.6 | 73.4 | (35.1-134.9) |
| Female | 8 | 4.5 | 176.8 | (76.1-348.4) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 40 | 35.6 | 112.4 | (80.3-153.1) |  | Male | 15 | 22.6 | 66.5 | (37.2-109.7) |
| Female | 35 | 30.5 | 114.8 | (79.9-159.6) |  | Female | 81 | 73.2 | 110.7 | (87.9-137.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 31 | 29.6 | 104.7 | (71.1-148.6) |  |  |  |  |  |  |
| Female | 14 | 12.0 | 116.8 | (63.8-195.9) |  | Female | 95 | 86.8 | 109.4 | (88.5-133.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 236 | 152.5 | 154.8 | (135.7-175.9) |  | Male | 1233 | 1117.9 | 110.3 | (104.2-116.6) |
| Female | 211 | 194.5 | 108.5 | (94.3-124.2) |  | Female | 1313 | 1363.3 | 96.3 | (91.2-101.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

105

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 56.6 | 93.7 | (70.2-122.5) |  | Male | 33 | 32.2 | 102.5 | (70.5-143.9) |
| Female | 13 | 20.5 | 63.4 | (33.7-108.4) |  | Female | 36 | 23.4 | 154.0 | (107.9-213.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 8.6 | 163.0 | (89.0-273.5) |  | Male | 6 | 10.7 | 56.2 | (20.5-122.4) |
| Female | 9 | 7.4 | 122.3 | (55.8-232.2) |  | Female | 8 | 9.0 | 88.9 | (38.3-175.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 35 | 28.8 | 121.6 | (84.7-169.1) |
| Female | 208 | 196.3 | 106.0 | (92.0-121.4) |  | Female | 18 | 26.7 | 67.5 | (40.0-106.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 29 | 22.1 | 131.3 | (87.9-188.6) |
| Female | 3 | 5.4 | nc | (nc-nc) |  | Female | 9 | 11.0 | 82.0 | (37.4-155.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 55.2 | 77.9 | (56.4-105.0) |  |  |  |  |  |  |
| Female | 53 | 56.2 | 94.3 | (70.6-123.4) |  | Female | 20 | 17.2 | 116.4 | (71.1-179.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 13.4 | 89.3 | (46.1-156.0) |  | Male | 12 | 19.1 | 62.9 | (32.5-109.8) |
| Female | 6 | 4.0 | 150.0 | (54.8-326.4) |  | Female | 13 | 20.8 | 62.6 | (33.3-107.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 169 | 159.0 | 106.3 | (90.9-123.6) |
| Female | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 32 | 26.6 | 120.1 | (82.1-169.6) |  | Male | 12 | 12.9 | 93.2 | (48.1-162.9) |
| Female | 16 | 16.4 | 97.4 | (55.6-158.2) |  | Female | 5 | 7.6 | 65.6 | (21.2-153.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 12 | 7.7 | 155.7 | (80.3-272.0) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 22 | 20.5 | 107.2 | (67.2-162.3) |  | Male | 7 | 9.9 | 70.5 | (28.3-145.3) |
| Female | 8 | 14.8 | 54.0 | (23.2-106.3) |  | Female | 14 | 28.3 | 49.5 | (27.0-83.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 17.0 | 94.4 | (53.9-153.2) |  |  |  |  |  |  |
| Female | 4 | 6.4 | nc | (nc-nc) |  | Female | 33 | 45.1 | 73.1 | (50.3-102.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 76 | 99.7 | 76.2 | (60.0-95.4) |  | Male | 648 | 662.8 | 97.8 | (90.4-105.6) |
| Female | 113 | 107.9 | 104.7 | (86.3-125.9) |  | Female | 643 | 686.9 | 93.6 | (86.5-101.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

106

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 56 | 36.6 | 152.9 | (115.5-198.6) |  | Male | 13 | 24.2 | 53.8 | (28.6-92.0) |
| Female | 16 | 13.8 | 115.8 | (66.1-188.1) |  | Female | 10 | 19.1 | 52.4 | (25.1-96.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 8.0 | nc | (nc-nc) |  | Male | 6 | 7.6 | 78.6 | (28.7-171.1) |
| Female | 12 | 6.3 | 191.0 | (98.6-333.7) |  | Female | 7 | 6.2 | 112.7 | (45.2-232.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 13 | 21.8 | 59.7 | (31.8-102.1) |
| Female | 143 | 149.0 | 96.0 | (80.9-113.1) |  | Female | 19 | 19.2 | 98.9 | (59.5-154.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 23 | 18.2 | 126.6 | (80.3-190.0) |
| Female | 11 | 5.1 | 216.0 | (107.7-386.5) |  | Female | 9 | 8.0 | 112.3 | (51.3-213.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 40.3 | 91.7 | (64.6-126.4) |  |  |  |  |  |  |
| Female | 43 | 40.1 | 107.1 | (77.5-144.3) |  | Female | 13 | 13.0 | 99.9 | (53.2-170.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 9.6 | 72.7 | (29.1-149.8) |  | Male | 13 | 13.2 | 98.5 | (52.4-168.5) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 6 | 14.0 | 43.0 | (15.7-93.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 99 | 118.1 | 83.8 | (68.1-102.0) |
| Female | 0 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 21.3 | 112.7 | (72.2-167.7) |  | Male | 15 | 8.9 | 167.6 | (93.7-276.5) |
| Female | 12 | 12.1 | 99.5 | (51.3-173.8) |  | Female | 7 | 5.5 | 128.4 | (51.4-264.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 5.6 | nc | (nc-nc) |  | Male | 6 | 6.7 | 88.9 | (32.5-193.6) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 15.8 | 88.7 | (48.5-148.9) |  | Male | 6 | 10.3 | 58.3 | (21.3-127.0) |
| Female | 13 | 11.4 | 113.7 | (60.5-194.5) |  | Female | 27 | 28.9 | 93.4 | (61.5-135.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 13.2 | 136.2 | (80.7-215.3) |  |  |  |  |  |  |
| Female | 6 | 4.5 | 134.7 | (49.2-293.2) |  | Female | 26 | 32.8 | 79.4 | (51.8-116.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 86 | 65.8 | 130.7 | (104.5-161.4) |  | Male | 486 | 489.4 | 99.3 | (90.7-108.5) |
| Female | 85 | 72.7 | 116.9 | (93.4-144.5) |  | Female | 519 | 510.6 | 101.7 | (93.1-110.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

107

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 8 | 12.1 | 66.2 | (28.5-130.5) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 8 | 13.5 | 59.4 | (25.6-117.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

108

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 17.5 | 68.7 | (35.4-120.0) |  | Male | 21 | 11.3 | 185.0 | (114.5-282.9) |
| Female | 3 | 6.3 | nc | (nc-nc) |  | Female | 10 | 9.2 | 108.7 | (52.0-199.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 3.5 | 201.2 | (80.6-414.7) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 12 | 10.2 | 117.6 | (60.7-205.4) |
| Female | 87 | 76.5 | 113.7 | (91.1-140.2) |  | Female | 7 | 9.1 | 76.6 | (30.7-157.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.6 | 81.1 | (32.5-167.2) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 0 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 19.5 | 107.5 | (66.5-164.3) |  |  |  |  |  |  |
| Female | 19 | 18.3 | 104.1 | (62.6-162.6) |  | Female | 8 | 6.5 | 123.8 | (53.3-243.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.6 | 131.6 | (48.1-286.5) |  | Male | 3 | 6.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 5 | 6.2 | 80.4 | (25.9-187.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 1.4 | 366.9 | (118.2-856.2) |  | Male | 66 | 54.2 | 121.7 | (94.1-154.9) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 10.0 | 119.7 | (61.8-209.1) |  | Male | 8 | 4.3 | 187.2 | (80.6-368.8) |
| Female | 8 | 6.0 | 134.3 | (57.8-264.6) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 7.2 | 139.1 | (66.6-255.9) |  | Male | 8 | 4.7 | 170.4 | (73.3-335.7) |
| Female | 6 | 5.2 | 115.5 | (42.2-251.3) |  | Female | 17 | 14.3 | 119.1 | (69.3-190.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 20 | 17.3 | 115.7 | (70.7-178.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 30.7 | 97.6 | (65.8-139.3) |  | Male | 252 | 228.2 | 110.4 | (97.2-124.9) |
| Female | 43 | 34.6 | 124.4 | (90.0-167.6) |  | Female | 267 | 248.4 | 107.5 | (95.0-121.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

109

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 59 | 66.6 | 88.5 | (67.4-114.2) |  | Male | 42 | 43.1 | 97.4 | (70.2-131.6) |
| Female | 21 | 25.8 | 81.4 | (50.4-124.5) |  | Female | 27 | 37.0 | 73.1 | (48.1-106.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 13.5 | 66.5 | (30.4-126.3) |  | Male | 14 | 13.6 | 102.6 | (56.1-172.2) |
| Female | 5 | 11.9 | 41.9 | (13.5-97.7) |  | Female | 11 | 11.7 | 93.7 | (46.7-167.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 41 | 38.7 | 105.9 | (76.0-143.6) |
| Female | 288 | 287.3 | 100.3 | (89.0-112.5) |  | Female | 27 | 36.4 | 74.2 | (48.9-107.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 28 | 31.5 | 88.8 | (59.0-128.4) |
| Female | 18 | 10.3 | 175.6 | (104.0-277.5) |  | Female | 10 | 15.3 | 65.2 | (31.2-120.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 64 | 72.2 | 88.7 | (68.3-113.2) |  |  |  |  |  |  |
| Female | 77 | 77.0 | 99.9 | (78.9-124.9) |  | Female | 27 | 24.8 | 108.7 | (71.6-158.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 17.0 | 58.8 | (28.1-108.1) |  | Male | 34 | 23.8 | 142.7 | (98.8-199.4) |
| Female | 5 | 5.0 | 100.2 | (32.3-233.9) |  | Female | 29 | 26.5 | 109.4 | (73.2-157.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  | Male | 201 | 204.1 | 98.5 | (85.3-113.1) |
| Female | 9 | 5.0 | 179.4 | (81.9-340.6) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 50 | 37.3 | 133.9 | (99.4-176.5) |  | Male | 22 | 16.2 | 136.0 | (85.2-205.9) |
| Female | 22 | 22.8 | 96.6 | (60.5-146.3) |  | Female | 8 | 10.5 | 76.3 | (32.8-150.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 9.9 | 60.5 | (22.1-131.8) |  | Male | 9 | 10.8 | 83.4 | (38.1-158.3) |
| Female | 3 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 24 | 27.8 | 86.3 | (55.3-128.4) |  | Male | 24 | 17.8 | 135.2 | (86.6-201.1) |
| Female | 21 | 21.9 | 96.1 | (59.4-146.8) |  | Female | 62 | 57.1 | 108.5 | (83.2-139.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 27 | 23.1 | 117.0 | (77.1-170.3) |  |  |  |  |  |  |
| Female | 7 | 8.4 | 83.2 | (33.3-171.4) |  | Female | 55 | 62.8 | 87.6 | (66.0-114.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 113 | 117.9 | 95.9 | (79.0-115.2) |  | Male | 831 | 863.9 | 96.2 | (89.8-103.0) |
| Female | 128 | 132.6 | 96.5 | (80.5-114.8) |  | Female | 949 | 973.5 | 97.5 | (91.4-103.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

110

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 27.8 | 97.2 | (64.0-141.4) |  | Male | 21 | 18.7 | 112.1 | (69.4-171.4) |
| Female | 10 | 10.0 | 99.8 | (47.8-183.6) |  | Female | 17 | 15.3 | 111.0 | (64.7-177.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.2 | 80.9 | (26.1-188.8) |  | Male | 11 | 5.9 | 185.8 | (92.6-332.5) |
| Female | 6 | 5.1 | 118.0 | (43.1-256.8) |  | Female | 5 | 4.7 | 107.4 | (34.6-250.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 15 | 16.9 | 88.9 | (49.7-146.6) |
| Female | 136 | 124.1 | 109.6 | (91.9-129.6) |  | Female | 13 | 14.7 | 88.5 | (47.1-151.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 14.5 | 117.0 | (68.1-187.3) |
| Female | 7 | 4.5 | 156.8 | (62.8-323.1) |  | Female | 2 | 6.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 31.6 | 91.8 | (61.5-131.9) |  |  |  |  |  |  |
| Female | 27 | 30.6 | 88.2 | (58.1-128.3) |  | Female | 12 | 10.4 | 115.0 | (59.3-200.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 7.5 | 134.2 | (64.2-246.8) |  | Male | 14 | 10.2 | 136.8 | (74.7-229.5) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 7 | 10.2 | 68.9 | (27.6-142.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 96 | 91.0 | 105.5 | (85.5-128.8) |
| Female | 5 | 2.1 | 242.5 | (78.2-566.0) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 16.9 | 82.8 | (45.2-139.0) |  | Male | 12 | 6.9 | 173.7 | (89.7-303.5) |
| Female | 17 | 9.5 | 178.5 | (103.9-285.8) |  | Female | 5 | 4.2 | 119.9 | (38.6-279.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 4.3 | 207.0 | (94.5-393.0) |  | Male | 8 | 4.5 | 177.7 | (76.5-350.2) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 12.2 | 98.4 | (50.8-171.9) |  | Male | 16 | 8.2 | 195.3 | (111.6-317.2) |
| Female | 6 | 8.8 | 68.5 | (25.0-149.2) |  | Female | 33 | 25.0 | 132.1 | (90.9-185.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 10.3 | 77.7 | (33.5-153.1) |  |  |  |  |  |  |
| Female | 0 | 3.4 | nc | (nc-nc) |  | Female | 38 | 26.7 | 142.4 | (100.8-195.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 43 | 50.2 | 85.7 | (62.0-115.4) |  | Male | 398 | 377.5 | 105.4 | (95.3-116.3) |
| Female | 42 | 53.2 | 79.0 | (56.9-106.7) |  | Female | 414 | 403.5 | 102.6 | (93.0-113.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

111